# Muscle Loss: Drug Versus Dieting

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-11-02

Canonical page: https://glpwatchdog.org/research/lean-mass-drug-versus-dieting

> Across 20 trials in 15,782 people, lean mass made up the same fraction of weight lost on incretin drugs as on dieting (p=0.42). Adding resistance training cut it from about a quarter to 17.5%.

## Key points

- Lean share of weight lost: 26.2% dieting, 25.4% tirzepatide, 35.2% semaglutide.
- Drugs vs lifestyle: no significant difference (p=0.42). Lean loss is a property of losing weight.
- Adding resistance training brought it to 17.5%, the only row that changes the answer.
- Semaglutide and tirzepatide intervals do not overlap; that difference is real and unexplained.

“These drugs make you lose muscle” is the most repeated criticism of GLP-1 medicines, and it is almost never accompanied by the comparison that would make it meaningful. A meta-analysis of 20 randomized trials in **15,782 people** supplied it: on incretin drugs, lean mass makes up broadly the same fraction of the weight lost as it does on dieting.[1]

## The comparison

*Proportion of total weight lost that was lean mass. Pooled from 20 randomized trials.*

| Intervention | Lean share of weight lost |
| --- | --- |
| Semaglutide | 35.2% (95% CI 31.5–38.9) |
| Liraglutide | 26.8% (95% CI 23.1–30.5) |
| Tirzepatide | 25.4% (95% CI 22.8–28.0) |
| **Lifestyle intervention** | **26.2% (95% CI 24.1–28.3)** |
| **Lifestyle plus resistance training** | **17.5% (95% CI 14.2–20.8)** |

The comparison between incretin drugs as a group and lifestyle intervention returned p=0.42, no significant difference.[1] Losing weight costs lean tissue. It costs about the same proportion whether the weight comes off through a drug or through dieting. The same arithmetic is behind the flatter buttocks people call [“Ozempic butt”](https://glpwatchdog.org/research/ozempic-butt-what-changes).

> Incretin drugs against lifestyle intervention: no significant difference in how much of the lost weight was lean mass (p=0.42).

## The row that actually helps

Adding resistance training brought the lean share down to **17.5%**, the most favorable profile in the analysis.[1] It is the only option in the table that cuts the lean share well below dieting’s 26.2%.

That is the practical conclusion, and [the exercise trial](https://glpwatchdog.org/research/exercise-plus-glp1-what-changes) reached it from a different direction: there the drug alone did nothing for physical fitness, and training did. Two independent lines of evidence point to the same instruction, which is to lift something.

> The authors’ own conclusion names three things: resistance training, adequate protein intake, and body composition monitoring built into weight-loss programs. None is exotic, and none is sold by anybody. Our [protein calculator](https://glpwatchdog.org/tools/glp1-protein-calculator) and [strength cheat sheet](https://glpwatchdog.org/research/cheat-sheets/glp1-exercise-strength-training-cheat-sheet) cover the first two.

## The difference between the drugs is not nothing

The class is not uniform, though. Semaglutide sits at 35.2% and tirzepatide at 25.4%, and those confidence intervals do not overlap.

This analysis cannot say what the gap means. It could reflect the drugs, the speed of loss they produce, the trial populations, or how body composition was measured in each study; heterogeneity across the pooled trials was moderate. The difference is real in the numbers but not yet explained, and it should not decide which one you pick.

## What lean mass does and does not tell you

Every figure above is a scan measurement. Whether the person can do more or less is a different question, and one that scans answer badly. In one study muscle volume fell 9.3% while chair-rise and walking speed both edged *better* (see [muscle volume versus muscle function](https://glpwatchdog.org/research/muscle-volume-versus-muscle-function)).

So the full picture is three-part: lean mass falls with any weight loss, at a similar proportion drug or diet; resistance training substantially reduces that share; and the mass number alone does not establish that anyone has been harmed. Nor does it mean the drug slowed metabolism; the calorimetry studies are in [does Ozempic slow your metabolism](https://glpwatchdog.org/research/does-ozempic-slow-your-metabolism).

## The pooled figure, across every drug class

A 2026 network meta-analysis pooled 41 randomized trials and 2,906 participants to place every major diabetes and obesity drug against a common reference on fat and lean mass at once.[2] Because every drug is set against the same reference, the numbers can be compared in a way that separate trials read side by side cannot.

*Mean difference against placebo. Both columns are losses.[2]*

| Drug | Fat mass | Lean body mass |
| --- | --- | --- |
| **Tirzepatide** | **−10.70 kg** (95% CI −13.42 to −7.99) | **−4.40 kg** (−7.58 to −1.22) |
| Liraglutide | Moderate reduction | −1.54 kg (−2.55 to −0.52) |
| Semaglutide | Moderate reduction | Not among the significant reductions |
| SGLT2 inhibitors | Modest | Minor losses |
| Metformin, insulin, DPP-4 inhibitors | Neutral or gain | Neutral |

Do the arithmetic on the tirzepatide row: 4.40 kg of lean against 10.70 kg of fat means lean tissue made up roughly **29%** of what was lost. That is the best pooled estimate available, and it sits close to what is generally expected of substantial weight loss by any means.

> **One node in that network is not a drug at all: liraglutide *plus exercise*.** It came second for fat loss, behind only tirzepatide, and the reviewers report that exercise mitigated the lean mass loss liraglutide caused on its own. Of everything in this analysis, that is the finding someone can act on.

The network also shows the opposite effect. Insulin glargine was associated with fat mass *gain*, which is the mirror image of what these drugs do and a reminder that “a diabetes drug” is not one thing.

## Frequently asked questions

### Do GLP-1 drugs cause more muscle loss than dieting?

No. Across 20 randomized trials in 15,782 people, lean mass made up 25% to 39% of the weight lost on incretin drugs and 26.2% on lifestyle intervention, with no significant difference between them (p=0.42). Lean loss is a property of losing weight rather than of the drugs.

### What actually reduces muscle loss?

Resistance training. Lifestyle intervention plus resistance training produced the most favorable profile in the analysis, with lean mass making up 17.5% of weight lost against roughly a quarter to a third for everything else.

### Is semaglutide worse than tirzepatide for muscle?

In this analysis semaglutide's lean share was 35.2% and tirzepatide's 25.4%, and those confidence intervals do not overlap. What explains the difference is unclear. It could be the drugs, the rate of weight loss, the trial populations or how composition was measured. It is not currently a reason to choose between them.

### How much protein should I be eating?

The authors name adequate protein alongside resistance training and body composition monitoring, without a single number, because requirements scale with body size and activity. Our protein calculator works a target from established intake figures.

### Does losing lean mass mean getting weaker?

Not necessarily. These are scan measurements, and a separate study found muscle volume falling 9.3% while chair-rise time and walking speed both improved slightly. Mass is easy to measure; function is what matters.

## References

1. Eisa N, Barood O. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes, Obesity and Metabolism. 2026. PMID: 41877354. https://pubmed.ncbi.nlm.nih.gov/41877354/
2. Rakhsha SS, Shahinfar H, Ebrahimi-Mousavi S, et al. Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis. Diabetes, Obesity and Metabolism. 2026. PMID: 42304171. https://pubmed.ncbi.nlm.nih.gov/42304171/

---

Cite as: GLP Watchdog, Nora Bissett, "Muscle Loss: Drug Versus Dieting", published 2026-08-19, updated 2026-11-02. https://glpwatchdog.org/research/lean-mass-drug-versus-dieting

Canonical HTML page: https://glpwatchdog.org/research/lean-mass-drug-versus-dieting

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
